|1.||Martin, Billy R: 4 articles (03/2010 - 10/2002)|
|2.||Carroll, F Ivy: 4 articles (03/2010 - 10/2002)|
|3.||Ma, Wei: 3 articles (03/2010 - 10/2002)|
|4.||Damaj, M Imad: 3 articles (03/2010 - 04/2003)|
|5.||Navarro, Hernán A: 3 articles (03/2010 - 10/2002)|
|6.||Cucchiaro, Giovanni: 3 articles (09/2008 - 04/2005)|
|7.||Johnson, M: 3 articles (12/2001 - 03/2000)|
|8.||Curzon, Peter: 2 articles (12/2006 - 10/2004)|
|9.||Chaijale, Nayla: 2 articles (06/2006 - 04/2005)|
|10.||Commons, Kathryn G: 2 articles (06/2006 - 04/2005)|
07/01/1998 - "Epibatidine and pain."
03/01/2001 - "Intrathecal injection of epibatidine alone did not alter pain behaviors, compared to vehicle-treated rats. "
12/28/2006 - "Several of the compounds reported in this study (i.e., 24, 25, 28, 30, 32, and 47) exhibit equivalent or greater affinity for the halpha4beta2 receptor relative to epibatidine, and like epibatidine, many exhibit robust analgesic efficacy in the rat formalin model of persistent pain."
11/01/2009 - "Epibatidine has shown antinociceptive effects in various pain models, being 200-fold more potent than morphine. "
06/01/2006 - "Epibatidine into the locus coeruleus resulted in a significant lower pain score in the second phase of the formalin test compared to control rats and was as effective as subcutaneous epibatidine. "
03/26/2010 - "In this study, we report the synthesis, receptor binding ([(3)H]epibatidine and [(125)I]iodoMLA), and in vivo pharmacological properties (mouse tail flick, hot plate, hypothermia, and spontaneous activity) of a series of 3'-(substituted phenyl)epibatidine analogues (5a-m). "
02/24/2005 - "Even though the alpha4beta2 binding affinity of several of the analogues were equal to that of epibatidine, all of the compounds were weak agonists in the antinociceptive, hypothermia, and spontaneous activity test in mice. "
10/22/2004 - "Known physiological responses elicited by epibatidine, such as hypothermia and micturition, were not affected by alpha3 aON treatment. "
04/01/2000 - "In contrast to (-)-nicotine and (+)-epibatidine, ABT-594 did not cause rotarod impairment at antinociceptive doses but did cause hypothermia and life-threatening adverse effects including seizures. "
|3.||Facial Pain (Myofacial Pain)
01/01/2001 - "Antihyperalgesic activity of epibatidine in the formalin model of facial pain."
01/01/2001 - "Taken together, these studies demonstrate that in both the acute and tonic phases of the formalin model of facial pain, epibatidine produces a neuronal nicotinic receptor-mediated antihyperalgesia that is both dose- and time-dependent. "
01/01/2001 - "Thus, the purpose of the present studies was to evaluate whether the neuronal nicotinic receptor agonist epibatidine possesses antihyperalgesic activity in the formalin model of facial pain. "
04/05/2012 - "In 11-14-day-old rats, we used in vitro carotid body/carotid sinus nerve preparation and whole body plethysmography to assess the carotid body and ventilatory responses to hypoxia (65 mmHg in vitro, 10% O2 in vivo) and to nicotinic receptor agonists (as an excitatory modulator of carotid body activity-nicotine 100 μM for in vitro studies, and epibatidine 5 μg/kg, i.p., which mainly acts on peripheral nicotinic receptors, for in vivo studies). "
04/11/2008 - "Epibatidine inhibited serotonin-induced currents mediated by endogenous 5-HT(3)Rs in neuroblastoma cell lines and 5-HT(3A)Rs expressed in HEK cells in a competitive manner. "
06/01/1998 - "We developed an immunoprecipitation radioassay by complexing epibatidine (125I-labeled high affinity agonist) to a Triton X-100-solubilized AChR antigen from peripheral neuroblastoma membranes. "
05/01/1998 - "The effects of epibatidine and nicotine were further investigated in human neuroblastoma SH-SY5Y cells (expressing alpha3, alpha5, beta2, and beta4 nAChR subunits). "
09/21/2000 - "Immunoprecipitation assays with iodine-125-labeled epibatidine and solubilized human neuroblastoma acetylcholine receptors were used to detect autoantibodies that bound to or blocked ganglionic receptors. "
11/26/1999 - "Chronic treatment with 17beta-estradiol (10(-10)-10(-5) M) alone did not change the number of [3H]epibatidine binding sites in human neuroblastoma SH-SY5Y cells and rat PC 12 cells, but significantly prevented the enhanced [3H]epibatidine binding in nicotine-treated PC 12 cells. "
|1.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|7.||Morphine (MS Contin)
|9.||Messenger RNA (mRNA)